SG11201901048VA - Pharmaceutical compositions and uses directed to lysosomal storage disorders - Google Patents
Pharmaceutical compositions and uses directed to lysosomal storage disordersInfo
- Publication number
- SG11201901048VA SG11201901048VA SG11201901048VA SG11201901048VA SG11201901048VA SG 11201901048V A SG11201901048V A SG 11201901048VA SG 11201901048V A SG11201901048V A SG 11201901048VA SG 11201901048V A SG11201901048V A SG 11201901048VA SG 11201901048V A SG11201901048V A SG 11201901048VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- begbroke
- pct
- lysosomal storage
- storage disorders
- Prior art date
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000012639 Balance disease Diseases 0.000 abstract 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1613828.1A GB201613828D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for lysosomal storage disorders |
GBGB1702552.9A GB201702552D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for lysosomal storage disorders |
GBGB1705762.1A GB201705762D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for lysosomal storage disorders |
GBGB1706854.5A GB201706854D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for lysosomal storage disorders |
PCT/IB2017/054928 WO2018029657A1 (en) | 2016-08-11 | 2017-08-11 | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901048VA true SG11201901048VA (en) | 2019-03-28 |
Family
ID=59859423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901048VA SG11201901048VA (en) | 2016-08-11 | 2017-08-11 | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Country Status (28)
Country | Link |
---|---|
US (3) | US11400067B2 (sr) |
EP (4) | EP4342461A3 (sr) |
JP (3) | JP7393943B2 (sr) |
KR (4) | KR20220154849A (sr) |
CN (1) | CN109843275A (sr) |
AU (2) | AU2017308864B2 (sr) |
BR (1) | BR112019002719A2 (sr) |
CA (1) | CA3033557A1 (sr) |
CY (2) | CY1121345T1 (sr) |
DK (2) | DK3482754T3 (sr) |
ES (2) | ES2849566T3 (sr) |
HK (1) | HK1253282B (sr) |
HR (2) | HRP20190344T1 (sr) |
HU (2) | HUE052837T2 (sr) |
IL (1) | IL264610B1 (sr) |
LT (2) | LT3359146T (sr) |
MA (2) | MA55947A (sr) |
MD (2) | MD3482754T2 (sr) |
ME (1) | ME03340B (sr) |
MX (2) | MX2019001577A (sr) |
PL (2) | PL3359146T3 (sr) |
PT (2) | PT3359146T (sr) |
RS (2) | RS61442B1 (sr) |
RU (2) | RU2749515C2 (sr) |
SG (1) | SG11201901048VA (sr) |
SI (2) | SI3482754T1 (sr) |
TN (1) | TN2019000032A1 (sr) |
WO (1) | WO2018029657A1 (sr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3359146T3 (pl) * | 2016-08-11 | 2019-07-31 | Intrabio Ltd | Kompozycje farmaceutyczne i zastosowania ukierunkowane na lizosomalne zaburzenia spichrzeniowe |
GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
MX2021006559A (es) * | 2018-12-06 | 2021-08-16 | Intrabio Ltd | Analogos deuterados de acetil-leucina. |
BR112021017203A2 (pt) | 2019-03-02 | 2021-12-14 | Intrabio Ltd | Leucina, acetil leucina e análogos relacionados para o tratamento de doenças |
EP3989962A1 (en) | 2019-06-28 | 2022-05-04 | IntraBio Ltd | Combination therapy with acetyl-leucine and miglustat |
WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2749512B1 (fr) * | 1996-06-10 | 1999-08-13 | Pf Medicament | Utilisation de l'acetyl dl leucine pour le traitement des tremblements |
AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
WO2009114729A2 (en) * | 2008-03-14 | 2009-09-17 | Irm Llc | Compounds, compositions and methods for treating lysosomal storage diseases and disorders |
TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
GB201114017D0 (en) * | 2011-08-15 | 2011-09-28 | Univ Dundee | Inhibitors against endosomal/ysosomal enzymes |
AU2013273473B2 (en) | 2012-06-06 | 2016-05-26 | Consiglio Nazionale Delle Ricerche | Allosteric chaperones and uses thereof |
KR102413756B1 (ko) * | 2016-08-11 | 2022-06-27 | 인트라바이오 리미티드 | 신경퇴행성 질병을 위한 치료제 |
PL3359146T3 (pl) * | 2016-08-11 | 2019-07-31 | Intrabio Ltd | Kompozycje farmaceutyczne i zastosowania ukierunkowane na lizosomalne zaburzenia spichrzeniowe |
-
2017
- 2017-08-11 PL PL17767933T patent/PL3359146T3/pl unknown
- 2017-08-11 CN CN201780062740.XA patent/CN109843275A/zh active Pending
- 2017-08-11 RS RS20210064A patent/RS61442B1/sr unknown
- 2017-08-11 ME MEP-2019-60A patent/ME03340B/me unknown
- 2017-08-11 KR KR1020227039341A patent/KR20220154849A/ko not_active IP Right Cessation
- 2017-08-11 MD MDE20190593T patent/MD3482754T2/ro unknown
- 2017-08-11 JP JP2019507811A patent/JP7393943B2/ja active Active
- 2017-08-11 PL PL18210763T patent/PL3482754T3/pl unknown
- 2017-08-11 EP EP24154769.4A patent/EP4342461A3/en active Pending
- 2017-08-11 CA CA3033557A patent/CA3033557A1/en active Pending
- 2017-08-11 MA MA055947A patent/MA55947A/fr unknown
- 2017-08-11 HU HUE18210763A patent/HUE052837T2/hu unknown
- 2017-08-11 RU RU2019106493A patent/RU2749515C2/ru active
- 2017-08-11 EP EP18210763.1A patent/EP3482754B1/en active Active
- 2017-08-11 KR KR1020197007024A patent/KR102412724B1/ko active IP Right Grant
- 2017-08-11 MX MX2019001577A patent/MX2019001577A/es unknown
- 2017-08-11 RU RU2021115932A patent/RU2021115932A/ru unknown
- 2017-08-11 RS RS20190334A patent/RS58478B1/sr unknown
- 2017-08-11 DK DK18210763.1T patent/DK3482754T3/da active
- 2017-08-11 HU HUE17767933A patent/HUE041914T2/hu unknown
- 2017-08-11 MD MDE20181131T patent/MD3359146T2/ro unknown
- 2017-08-11 ES ES18210763T patent/ES2849566T3/es active Active
- 2017-08-11 BR BR112019002719-0A patent/BR112019002719A2/pt active Search and Examination
- 2017-08-11 MA MA43876A patent/MA43876B1/fr unknown
- 2017-08-11 DK DK17767933.9T patent/DK3359146T3/en active
- 2017-08-11 AU AU2017308864A patent/AU2017308864B2/en active Active
- 2017-08-11 LT LTEP17767933.9T patent/LT3359146T/lt unknown
- 2017-08-11 LT LTEP18210763.1T patent/LT3482754T/lt unknown
- 2017-08-11 KR KR1020247021734A patent/KR20240110078A/ko active Application Filing
- 2017-08-11 SI SI201730613T patent/SI3482754T1/sl unknown
- 2017-08-11 SG SG11201901048VA patent/SG11201901048VA/en unknown
- 2017-08-11 PT PT17767933T patent/PT3359146T/pt unknown
- 2017-08-11 PT PT182107631T patent/PT3482754T/pt unknown
- 2017-08-11 EP EP20215877.0A patent/EP3865126A1/en active Pending
- 2017-08-11 ES ES17767933T patent/ES2716133T3/es active Active
- 2017-08-11 TN TNP/2019/000032A patent/TN2019000032A1/en unknown
- 2017-08-11 IL IL264610A patent/IL264610B1/en unknown
- 2017-08-11 SI SI201730032T patent/SI3359146T1/sl unknown
- 2017-08-11 EP EP17767933.9A patent/EP3359146B1/en active Active
- 2017-08-11 KR KR1020227009897A patent/KR102467953B1/ko active IP Right Grant
- 2017-08-11 WO PCT/IB2017/054928 patent/WO2018029657A1/en active Application Filing
- 2017-08-11 US US16/324,301 patent/US11400067B2/en active Active
-
2018
- 2018-10-02 HK HK18112571.2A patent/HK1253282B/zh unknown
-
2019
- 2019-02-07 MX MX2021008432A patent/MX2021008432A/es unknown
- 2019-02-21 HR HRP20190344TT patent/HRP20190344T1/hr unknown
- 2019-03-08 CY CY20191100279T patent/CY1121345T1/el unknown
-
2021
- 2021-01-12 CY CY20211100017T patent/CY1123844T1/el unknown
- 2021-01-29 HR HRP20210153TT patent/HRP20210153T1/hr unknown
-
2022
- 2022-01-07 JP JP2022001694A patent/JP2022050564A/ja active Pending
- 2022-06-30 US US17/854,027 patent/US20220331278A1/en active Pending
-
2023
- 2023-05-10 AU AU2023202903A patent/AU2023202903A1/en active Pending
-
2024
- 2024-02-02 US US18/430,858 patent/US20240197663A1/en active Pending
- 2024-02-27 JP JP2024027864A patent/JP2024059863A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof |